AVTX
Avalo’s back at the ATM, but bigger
Avalo Therapeutics says it priced a $375 million public offering, which is a pretty loud way of saying, “We need more runway.” In biotech, this is the financial version of packing an extra charger before a long flight — not glamorous, but very necessary if you want to make it to the next milestone.
Why you should care
For shareholders, the obvious tradeoff is dilution. More shares usually means each existing slice of the pie gets a little thinner. But if Avalo can turn that capital into clinical progress, regulatory wins, or a stronger balance sheet, the market may forgive the snack-size hit to ownership.
The investor math
The offering matters because it changes the company’s financial weather:
- Bull case: more cash means more shots on goal and less near-term financing panic.
- Bear case: the company may be raising money because the road ahead is expensive, uncertain, or both.
- Stock reaction: biotech offerings often get a stern side-eye from traders, at least until the cash gets deployed into something exciting.
Big picture: this is the kind of move that can keep a biotech alive long enough to matter — but it can also remind you that science is expensive and Wall Street rarely does charity.